Varian has received FDA 510(k) clearance for its Calypso® Anchored Beacon® transponder, a device that detects even slight movements of a tumor in three dimensions and helps clinicians deliver lung stereotactic body radiotherapy (SBRT) more precisely.
“The 510(k) clearance of the Anchored Beacon transponder expands the application of the Calypso system platform,” said Ed Vertatschitsch, vice president, Global Portfolio Solutions. “Using the Calypso system and Anchored Beacon transponder, clinicians can deliver dose to lung tumors with increased confidence and accuracy.
The Calypso system works by tracking the Anchored Beacon transponders after they have been implanted in small airways in or near the targeted tumor. The transponders emit non-ionizing electromagnetic signals that are tracked in real time and used to keep the treatment beam on target.
For more information on the Calypso system, visit www.varian.com/calypso.